Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy, David Geffen School of Medicine at UCLA, 650 Charles E. Young Drive South 43-229 CHS, Los Angeles, CA 90095-1690, USA.
Pulmonary Vascular Disease Program, Acute and Chronic Thromboembolic Disease Program, Pulmonary and Critical Care Division, Division of Pulmonary, Critical Care, & Sleep Medicine, David Geffen School of Medicine at UCLA, 650 Charles E. Young Drive South 43-229 CHS, Los Angeles, CA 90095-1690, USA.
Cardiol Clin. 2022 Feb;40(1):13-27. doi: 10.1016/j.ccl.2021.08.002.
Pulmonary arterial hypertension is a rare disease characterized by pulmonary microvasculature remodeling leading to right ventricular failure and death. Medical management of pulmonary hypertension has grown increasingly complex as more therapeutic agents have been developed. Evolving treatment strategies leveraging the endothelin, nitric oxide, and prostacyclin pathways lead to improved exercise capacity and outcomes in patients; however, significant opportunities for advancement remain.
肺动脉高压是一种罕见的疾病，其特征是肺微血管重构导致右心衰竭和死亡。随着更多治疗药物的开发，肺动脉高压的医学治疗变得越来越复杂。利用内皮素、一氧化氮和前列环素途径的不断发展的治疗策略可提高患者的运动能力和改善预后；然而，仍有很大的改进空间。
Zotero 插件